ESR1 and neoplasm: ESR1 mutations leading to constitutive activation of Estrogen Receptor alpha (ERα) were selected by pharmacological treatments leading to reduction of estrogen levels in peripheral blood and in tumor microenvironment, such as LHRH analogues (LHRHa) and aromatase inhibitors (AIs) [5,6].